Figure 2
From: Enhancement of anti-STLV-1/HTLV-1 immune responses through multimodal effects of anti-CCR4 antibody
Immune responses induced by mogamulizumab.
(a) Antibody-dependent phagocytosis by macrophages. PKH26-labeled monkey CD4+ T cells from infected JMs were treated with mogamulizumab and co-cultured with monocyte-derived macrophages (MDM) and CD11b+PHK26+ cells were measured. (b) Mogamulizumab depletes CCR4+CD4+ T cells from PBMCs of an STLV-1 infected monkey in vitro. (c) Mogamulizumab induces cytokine production in STLV-1 specific CD8 T cells in ex vivo culture. PBMCs from unvaccinated STLV-1 infected monkeys were cultured with mogamulizumab and then stimulated with auto-PBMCs that were pulsed with sTax (PA: sTax1–164, PB: sTax151–353) or SBZ (PA: SBZ1–104, PB: SBZ91–206) peptides and labeled with tracer-dye. (d) IFN-γ and TNF-α production were measured in the tracer-dye negative population. The data from non-pulsed PBMCs is shown as a reference.
